Ocular Therapeutix, Inc.
General ticker "OCUL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2B (TTM average)
Ocular Therapeutix, Inc. does not follow the US Stock Market performance with the rate: -17.9%.
Estimated limits based on current volatility of 1.8%: low 8.27$, high 8.57$
Factors to consider:
- Earnings expected soon, date: 2026-08-04 bmo
- Total employees count: 325 (+18.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Economic downturns and volatility, Commercialization failure, Capital constraints, Intellectual property risks
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.71$, 18.90$]
- 2026-12-31 to 2027-12-31 estimated range: [7.65$, 17.05$]
Financial Metrics affecting the OCUL estimates:
- Negative: with PPE of -8.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.74 <= 0.30
- Positive: Investing cash flow per share per price, % of -0.51 > -0.65
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.51 <= 0.75
Short-term OCUL quotes
Long-term OCUL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $58.44MM | $63.72MM | $51.95MM |
| Operating Expenses | $140.82MM | $235.50MM | $321.97MM |
| Operating Income | $-82.38MM | $-171.78MM | $-270.02MM |
| Non-Operating Income | $1.65MM | $-21.73MM | $4.08MM |
| Interest Expense | $11.34MM | $13.58MM | $11.84MM |
| R&D Expense | $61.05MM | $127.64MM | $197.10MM |
| Income(Loss) | $-80.74MM | $-193.51MM | $-265.94MM |
| Net Income(Loss)* | $-80.74MM | $-193.51MM | $-265.94MM |
| Stockholders Equity | $91.13MM | $315.34MM | $654.31MM |
| Inventory | $2.31MM | $3.04MM | $3.56MM |
| Assets | $252.06MM | $457.94MM | $808.06MM |
| Operating Cash Flow | $-70.23MM | $-134.68MM | $-204.88MM |
| Capital expenditure | $6.09MM | $1.29MM | $12.01MM |
| Investing Cash Flow | $-6.09MM | $-1.29MM | $-11.88MM |
| Financing Cash Flow | $169.83MM | $332.11MM | $561.72MM |
| Earnings Per Share** | $-1.01 | $-1.22 | $-1.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.